

Date: 16th February, 2022

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai - 400051

Dear Sir/Madam,

Sub: Outcome of the Analyst/Institutional Investor Meetings/ Earnings Call under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

This is further to our letter dated 14th February 2022, wherein we had given you an advance intimation of the upcoming Analyst or Institutional Investor Interactions in terms of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We wish to inform you that the Company today i.e. on 16th February 2022, through Teleconference, conducted the Q3FY22 Earnings Con-Call with respect to the Unaudited Standalone and Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended 31st December, 2021. The interactions used a Q&A format. The Investor Presentation referred was uploaded on the Stock Exchange(s) and Company's Website on 15th February 2022.

Audio recording and transcript of the proceedings would be made available on our website in due course :

<https://www.medplusindia.com/investor-presentations.jsp>

Note: No Unpublished Price Sensitive Information (UPSI) was shared during any of these interactions.

This is for your information and record.

For and on behalf of Medplus Health Services Limited



Shilpi Keswani
Company Secretary & Compliance Officer

